Northwest Biotherapeutics (NWBO) Non-Current Assets (2010 - 2026)

Northwest Biotherapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $73.8 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 223.63% year-over-year to $73.8 million in Q1 2026; TTM through Mar 2026 was $73.8 million, a 223.63% increase from a year earlier, with the FY2025 full-year figure at $75.8 million, up 234.3% from the prior year.
• Non-Current Assets retreated to $73.8 million in Q1 2026 per NWBO's latest filing, from $75.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $75.8 million in Q4 2025 and bottomed at $19.3 million in Q3 2022.
• The 5-year median for Non-Current Assets is $23.4 million (2023), against an average of $28.8 million.
• Across the five-year window, Non-Current Assets dropped 11.77% in 2022 and soared 234.3% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $21.9 million in 2022, then climbed by 8.41% to $23.7 million in 2023, then dropped by 4.52% to $22.7 million in 2024, then surged by 234.3% to $75.8 million in 2025, then slipped by 2.54% to $73.8 million in 2026.
• Per Business Quant, the three latest NWBO Non-Current Assets figures stand at $73.8 million (Q1 2026), $75.8 million (Q4 2025), and $23.4 million (Q3 2025).